Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Acadia Pharmaceuticals Inc.

< Previous 1 2 3 4 Next >
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Stock Trading Halted Today
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD STOK
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.